Body weight and adiposity
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
Records whose assigned subject headings cover body mass, adiposity, energy intake or the agents indexed against them. 103 of the 186 records indexed across this publication's scope carry at least one of them, covering all 17 compounds.
Assignment is mechanical. A record sits under this endpoint because the indexer attached one of the subject headings listed further down, not because anyone read it. The cell counts records. It does not report a result, a direction or a magnitude, and nothing in the corpus would let it.
Record coverage by compound and record class
| Compound | Ph 3 | Ph 2 | Ph 1 | Trial, no phase | Review | Other | All |
|---|---|---|---|---|---|---|---|
| Amylin | 0 | 0 | 0 | 0 | 2 [92, 103] | 1 [101] | 3 |
| Cagrilintide | 3 [25, 53, 54] | 0 | 0 | 0 | 1 [21] | 3 [31, 37, 57] | 7 |
| Dulaglutide | 1 [75] | 0 | 0 | 0 | 0 | 0 | 1 |
| Eloralintide | 0 | 1 [64] | 1 [63] | 0 | 4 [18, 30, 41, 42] | 1 [13] | 7 |
| Exenatide | 1 [81] | 0 | 0 | 1 [87] | 0 | 1 [96] | 3 |
| GLP-1 | 0 | 1 [84] | 0 | 0 | 3 [80, 82, 97] | 3 [93, 94, 95] | 7 |
| Liraglutide | 3 [74, 77, 79] | 1 [83] | 0 | 1 [76] | 0 | 2 [78, 85] | 7 |
| Lixisenatide | 0 | 1 [89] | 0 | 3 [88, 90, 91] | 0 | 1 [86] | 5 |
| Maridebart cafraglutide | 0 | 1 [55] | 1 [66] | 0 | 2 [2, 29] | 1 [9] | 5 |
| Mazdutide | 4 [10, 11, 34, 52] | 1 [23] | 1 [60] | 1 [7] | 4 [19, 20, 40, 62] | 0 | 11 |
| Orforglipron | 3 [8, 27, 39] | 0 | 0 | 0 | 3 [15, 16, 28] | 2 [24, 33] | 8 |
| Petrelintide | 0 | 0 | 1 [26] | 0 | 3 [18, 41, 42] | 1 [56] | 5 |
| Pramlintide | 0 | 0 | 0 | 1 [102] | 1 [98] | 2 [99, 100] | 4 |
| Retatrutide | 0 | 1 [58] | 0 | 1 [4] | 2 [1, 12] | 3 [3, 17, 49] | 7 |
| Semaglutide | 2 [51, 73] | 0 | 0 | 1 [67] | 0 | 4 [68, 69, 71, 72] | 7 |
| Survodutide | 4 [5, 6, 35, 36] | 2 [38, 48] | 0 | 2 [32, 43] | 2 [22, 61] | 2 [14, 59] | 12 |
| Tirzepatide | 6 [44, 46, 50, 51, 65, 70] | 0 | 0 | 2 [45, 47] | 0 | 1 [71] | 9 |
Column keys: Ph 3 phase 3; Ph 2 phase 2; Ph 1 phase 1; Trial, no phase trial, no phase assigned; Review review or synthesis; Other not a registered trial record. Phase is read from the publication type the indexer assigned to each record, never from its title.
A zero cell records that no indexed record for that compound carries one of these subject headings. It is the absence of a retrieved report, never the absence of the thing itself. The full record set for each compound is held on its own trial page.
Subject headings that place a record here
The full set is fixed and printed here so the assignment can be checked by hand against the method. 19 of the 19 headings in the set occur on at least one record in scope.
| Subject heading | Records |
|---|---|
| Obesity | 80 |
| Weight Loss | 52 |
| Anti-Obesity Agents | 38 |
| Body Weight | 27 |
| Body Mass Index | 25 |
| Overweight | 6 |
| Adipose Tissue | 5 |
| Eating | 4 |
| Caloric Restriction | 3 |
| Body Composition | 2 |
| Body Size | 2 |
| Energy Metabolism | 2 |
| Leptin | 2 |
| Mice, Obese | 2 |
| Absorptiometry, Photon | 1 |
| Appetite Depressants | 1 |
| Appetite Regulation | 1 |
| Waist Circumference | 1 |
| Weight Gain | 1 |
The records
103 distinct records, newest first within each class. A record indexed under more than one compound is listed once and named under each.
Phase 3 — 26 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 5 | pmid:41187967 | 2026 | Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) Diabetes, obesity & metabolism · Clinical Trial, Phase III, research-article | human trial | Survodutide | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Injections, Subcutaneous; Double-Blind Method |
| 6 | pmid:41216778 | 2026 | Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes Diabetes, obesity & metabolism · Clinical Trial, Phase III, research-article | human trial | Survodutide | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Receptors, Glucagon; Anti-Obesity Agents; Hypoglycemic Agents; Body Mass Index |
| 8 | pmid:41275875 | 2026 | Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial Lancet (London, England) · Clinical Trial, Phase III, Multicenter Study | human trial | Orforglipron | Humans; Diabetes Mellitus, Type 2; Obesity; Fluorine Compounds; Oxadiazoles; Hypoglycemic Agents; Body Mass Index; Treatment Outcome |
| 10 | pmid:41407859 | 2026 | Mazdutide versus placebo in Chinese adults with type 2 diabetes Nature · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Mazdutide | Humans; Diabetes Mellitus, Type 2; Weight Loss; Blood Glucose; Peptides; Receptors, Glucagon; Placebos; Hypoglycemic Agents |
| 11 | pmid:41407860 | 2026 | Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes Nature · Clinical Trial, Phase III, Comparative Study | human trial | Mazdutide | Humans; Diabetes Mellitus, Type 2; Body Weight; Peptides; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Adult |
| 25 | pmid:42009015 | 2026 | Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial The lancet. Diabetes & endocrinology · Clinical Trial, Phase III, Multicenter Study | human trial | Cagrilintide | Humans; Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Treatment Outcome; Drug Therapy, Combination; Double-Blind Method; Adult |
| 27 | pmid:42120723 | 2026 | Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Nature medicine · Clinical Trial, Phase III, research-article | human trial | Orforglipron | Humans; Obesity; Weight Loss; Fluorine Compounds; Oxadiazoles; Double-Blind Method; Adult; Middle Aged |
| 34 | pmid:42251595 | 2026 | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial JAMA · Clinical Trial, Phase III, Multicenter Study | human trial | Mazdutide | Humans; Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Diarrhea; Nausea; Vomiting |
| 35 | pmid:42252333 | 2026 | Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Nature medicine · Clinical Trial, Phase III, Randomized Controlled Trial | human trial | Survodutide | Liver; Humans; Fatty Liver; Obesity; Magnetic Resonance Imaging; Body Mass Index; Double-Blind Method; Adult |
| 36 | pmid:42253238 | 2026 | Survodutide Once Weekly for the Treatment of Adults with Obesity The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Survodutide | Humans; Obesity; Weight Loss; Receptors, Glucagon; Anti-Obesity Agents; Drugs, Investigational; Body Mass Index; Treatment Outcome |
| 39 | pmid:42338042 | 2026 | Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials Diabetes, obesity & metabolism · Clinical Trial, Phase III, research-article | human trial | Orforglipron | Liver; Humans; Diabetes Mellitus, Type 2; Obesity; Fluorine Compounds; Benzhydryl Compounds; Oxadiazoles; Alanine Transaminase |
| 44 | pmid:39536238 | 2025 | Tirzepatide for Obesity Treatment and Diabetes Prevention The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Tirzepatide | Humans; Gastrointestinal Diseases; Diabetes Mellitus, Type 2; Prediabetic State; Obesity; Disease Progression; Body Weight; Weight Loss |
| 46 | pmid:39555826 | 2025 | Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Tirzepatide | Humans; Cardiovascular Diseases; Obesity; Stroke Volume; Body Mass Index; Treatment Outcome; Follow-Up Studies; Double-Blind Method |
| 50 | pmid:39996356 | 2025 | Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight Diabetes, obesity & metabolism · Clinical Trial, Phase III, research-article | human trial | Tirzepatide | Humans; Obesity; Weight Loss; Anti-Obesity Agents; Absorptiometry, Photon; Body Mass Index; Treatment Outcome; Body Composition |
| 51 | pmid:40353578 | 2025 | Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England journal of medicine · Clinical Trial, Phase III, Comparative Study | human trial | Semaglutide, Tirzepatide | Humans; Obesity; Body Weight; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Injections, Subcutaneous; Maximum Tolerated Dose |
| 52 | pmid:40421736 | 2025 | Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Mazdutide | Humans; Obesity; Weight Loss; Peptides; Receptors, Glucagon; Anti-Obesity Agents; Body Mass Index; Treatment Outcome |
| 53 | pmid:40544432 | 2025 | Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Cagrilintide | Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Obesity; Weight Loss; Blood Glucose; Drug Combinations; Body Mass Index |
| 54 | pmid:40544433 | 2025 | Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Cagrilintide | Humans; Hypertension; Obesity; Weight Loss; Anti-Obesity Agents; Drug Combinations; Body Mass Index; Treatment Outcome |
| 65 | pmid:38078870 | 2024 | Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Tirzepatide | Humans; Obesity; Weight Loss; Gastric Inhibitory Polypeptide; Anti-Obesity Agents; Treatment Outcome; Withholding Treatment; Injections, Subcutaneous |
| 70 | pmid:38912654 | 2024 | Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity The New England journal of medicine · Clinical Trial, Phase III, research-article | human trial | Tirzepatide | Humans; Sleep Apnea, Obstructive; Obesity; Body Weight; Gastric Inhibitory Polypeptide; C-Reactive Protein; Treatment Outcome; Severity of Illness Index |
| 73 | pmid:39476339 | 2024 | Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Semaglutide | Humans; Arthralgia; Osteoarthritis, Knee; Obesity; Weight Loss; Pain Measurement; Body Mass Index; Combined Modality Therapy |
| 74 | pmid:35015037 | 2022 | Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial JAMA · Clinical Trial, Phase III, research-article | human trial | Liraglutide | Humans; Diabetes Mellitus; Obesity; Body Weight; Weight Loss; Placebos; Hypoglycemic Agents; Treatment Outcome |
| 75 | pmid:35914543 | 2022 | Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial The lancet. Diabetes & endocrinology · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Dulaglutide | Humans; Diabetes Mellitus, Type 2; Body Weight; Gastric Inhibitory Polypeptide; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Double-Blind Method |
| 77 | pmid:32233338 | 2020 | A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity The New England journal of medicine · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Liraglutide | Humans; Gastrointestinal Diseases; Blood Glucose; Body Mass Index; Combined Modality Therapy; Injections, Subcutaneous; Double-Blind Method; Adolescent |
| 79 | pmid:31186120 | 2019 | Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial Lancet (London, England) · Clinical Trial, Phase III, Comparative Study | human trial | Liraglutide | Humans; Diabetes Mellitus, Type 2; Body Weight; Metformin; Treatment Outcome; Administration, Oral; Injections, Subcutaneous; Double-Blind Method |
| 81 | pmid:29246950 | 2018 | Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial Diabetes care · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Exenatide | Venoms; Humans; Diabetes Mellitus, Type 2; Body Weight; Metformin; Blood Glucose; Peptides; Delayed-Action Preparations |
Phase 2 — 9 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 23 | pmid:41875890 | 2026 | Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial Med (New York, N.Y.) · Clinical Trial, Phase II, Randomized Controlled Trial | human trial | Mazdutide | Humans; Obesity; Weight Loss; Peptides; Anti-Obesity Agents; Body Mass Index; Treatment Outcome; Double-Blind Method |
| 38 | pmid:42331726 | 2026 | Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity Diabetes, obesity & metabolism · Clinical Trial, Phase II, research-article | human trial | Survodutide | Humans; Diabetes Mellitus, Type 2; Insulin Resistance; Obesity; Metformin; Glucagon; Blood Glucose; Peptide Fragments |
| 48 | pmid:39821928 | 2025 | Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist Diabetes, obesity & metabolism · Clinical Trial, Phase II, research-article | human trial | Survodutide | Humans; Obesity; Hypoglycemic Agents; Body Mass Index; Treatment Outcome; Double-Blind Method; Sex Factors; Adolescent |
| 55 | pmid:40549887 | 2025 | Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial The New England journal of medicine · Clinical Trial, Phase II, Multicenter Study | human trial | Maridebart cafraglutide | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Receptors, Gastrointestinal Hormone; Anti-Obesity Agents; Immunoconjugates; Body Mass Index |
| 58 | pmid:40609566 | 2025 | Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial The lancet. Diabetes & endocrinology · Clinical Trial, Phase II, Multicenter Study | human trial | Retatrutide | Humans; Diabetes Mellitus, Type 2; Fatty Acids; Peptides; Recombinant Fusion Proteins; Hypoglycemic Agents; Double-Blind Method; Body Composition |
| 64 | pmid:41207310 | 2025 | Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Lancet (London, England) · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't | human trial | Eloralintide | Humans; Obesity; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Double-Blind Method; Dose-Response Relationship, Drug; Adult |
| 83 | pmid:30122305 | 2018 | Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial Lancet (London, England) · Clinical Trial, Phase II, Comparative Study | human trial | Liraglutide | Humans; Obesity; Weight Loss; Blood Glucose; Placebos; Hypoglycemic Agents; Body Mass Index; Treatment Outcome |
| 84 | pmid:30293770 | 2018 | Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Lancet (London, England) · Clinical Trial, Phase II, Multicenter Study | human trial | GLP-1 | Humans; Diabetes Mellitus, Type 2; Weight Loss; Gastric Inhibitory Polypeptide; Blood Glucose; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome |
| 89 | pmid:27284114 | 2016 | Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial Diabetes care · Clinical Trial, Phase II, Comparative Study | human trial | Lixisenatide | Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Body Weight; Metformin; Blood Glucose; Peptides; Drug Combinations |
Phase 1 — 4 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 26 | pmid:42017294 | 2026 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials Diabetes, obesity & metabolism · research-article, Clinical Trial, Phase I | human trial | Petrelintide | Humans; Obesity; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Injections, Subcutaneous; Double-Blind Method; Dose-Response Relationship, Drug |
| 60 | pmid:40832785 | 2025 | Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial Diabetes, obesity & metabolism · research-article, Clinical Trial, Phase I | human trial | Mazdutide | Humans; Obesity; Body Weight; Weight Loss; Peptides; Anti-Obesity Agents; Treatment Outcome; Injections, Subcutaneous |
| 63 | pmid:41109426 | 2025 | Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept Molecular metabolism · research-article, Clinical Trial, Phase I | human trial | Eloralintide | Animals; Humans; Rats; Rats, Sprague-Dawley; Obesity; Anti-Obesity Agents; Adult; Middle Aged |
| 66 | pmid:38316982 | 2024 | A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings Nature metabolism · research-article, Clinical Trial, Phase I | human trial | Maridebart cafraglutide | Animals; Humans; Mice; Obesity; Weight Loss; Peptides; Male; Glucagon-Like Peptide 1 |
Trial, no phase assigned — 13 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 4 | pmid:41160422 | 2026 | Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · Clinical Trial Protocol, research-article | other | Retatrutide | Humans; Diabetes Mellitus, Type 2; Obesity; Fatty Acids; Peptides; Hypoglycemic Agents; Kidney Function Tests; Glomerular Filtration Rate |
| 7 | pmid:41260459 | 2026 | Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial Contemporary clinical trials · Clinical Trial Protocol | other | Mazdutide | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Metformin; Blood Glucose; Peptides; Hypoglycemic Agents |
| 32 | pmid:42219222 | 2026 | Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial Diabetes, obesity & metabolism · Clinical Trial Protocol, methods-article | other | Survodutide | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Double-Blind Method; Adult |
| 43 | pmid:39495965 | 2025 | Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2) Obesity (Silver Spring, Md.) · Clinical Trial Protocol, research-article | other | Survodutide | Humans; Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Glucagon; Hypoglycemic Agents; Body Mass Index |
| 45 | pmid:39551891 | 2025 | Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial Nature medicine · research-article, Randomized Controlled Trial | human trial | Tirzepatide | Humans; Obesity; Natriuretic Peptide, Brain; Peptide Fragments; C-Reactive Protein; Stroke Volume; Blood Pressure; Aged |
| 47 | pmid:39566869 | 2025 | Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy Journal of the American College of Cardiology · Multicenter Study, Randomized Controlled Trial | human trial | Tirzepatide | Heart Ventricles; Adipose Tissue; Humans; Obesity; Magnetic Resonance Imaging, Cine; Stroke Volume; Double-Blind Method; Aged |
| 67 | pmid:38587233 | 2024 | Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes The New England journal of medicine · Randomized Controlled Trial | human trial | Semaglutide | Humans; Diabetes Mellitus, Type 2; Obesity; Stroke Volume; Double-Blind Method; Glucagon-Like Peptides; Heart Failure; Glucagon-Like Peptide-1 Receptor Agonists |
| 76 | pmid:33951361 | 2021 | Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined The New England journal of medicine · Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Liraglutide | Adipose Tissue; Humans; Obesity; Weight Loss; Anti-Obesity Agents; Body Size; Combined Modality Therapy; Exercise Therapy |
| 87 | pmid:27106272 | 2016 | Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy Diabetes, obesity & metabolism · Randomized Controlled Trial | human trial | Exenatide | Myocardium; Liver; Pancreas; Heart; Pericardium; Adipose Tissue; Venoms; Humans |
| 88 | pmid:27222510 | 2016 | Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial Diabetes care · Randomized Controlled Trial | human trial | Lixisenatide | Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Body Weight; Metformin; Blood Glucose; Peptides; Hypoglycemic Agents |
| 90 | pmid:27311491 | 2016 | Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial Diabetes care · Randomized Controlled Trial | human trial | Lixisenatide | Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Body Weight; Metformin; Blood Glucose; Peptides; Hypoglycemic Agents |
| 91 | pmid:27650977 | 2016 | Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial Diabetes care · Multicenter Study, Randomized Controlled Trial | human trial | Lixisenatide | Humans; Diabetes Mellitus, Type 2; Body Weight; Metformin; Insulin; Blood Glucose; Peptides; Drug Combinations |
| 102 | pmid:18753666 | 2008 | Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity Diabetes care · research-article, Randomized Controlled Trial | human trial | Pramlintide | Humans; Weight Loss; Amyloid; Placebos; Hypoglycemic Agents; Body Mass Index; Body Size; Follow-Up Studies |
Review or synthesis — 24 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 1 | pmid:39724554 | 2026 | The First Triple Agonist for Antiobesity: Retatrutide Cardiology in review · Review | other | Retatrutide | Humans; Obesity; Weight Loss; Fatty Acids; Peptides; Anti-Obesity Agents; Glucagon-Like Peptide-1 Receptor Agonists |
| 2 | pmid:41054801 | 2026 | Novel GLP-1-based Medications for Type 2 Diabetes and Obesity Endocrine reviews · Review | other | Maridebart cafraglutide | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucagon-Like Peptide-1 Receptor Agonists |
| 12 | pmid:41545327 | 2026 | The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities Clinical pharmacology in drug development · Review | other | Retatrutide | Animals; Humans; Cardiovascular Diseases; Obesity; Gastric Inhibitory Polypeptide; Fatty Acids; Peptides; Receptors, Glucagon |
| 15 | pmid:41640110 | 2026 | Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis Diabetes technology & therapeutics · Meta-Analysis, Systematic Review | other | Orforglipron | Humans; Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Fluorine Compounds; Oxadiazoles; Blood Glucose |
| 16 | pmid:41683830 | 2026 | Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes International journal of molecular sciences · review-article, Review | other | Orforglipron | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Fluorine Compounds; Oxadiazoles; Hypoglycemic Agents; Administration, Oral |
| 18 | pmid:41747885 | 2026 | Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes Peptides · Review | other | Eloralintide, Petrelintide | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Glucagon-Like Peptides; Islet Amyloid Polypeptide; Receptors, Islet Amyloid Polypeptide |
| 19 | pmid:41804840 | 2026 | Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials Diabetes, obesity & metabolism · Meta-Analysis, Review | other | Mazdutide | Humans; Obesity; Weight Loss; Peptides; Anti-Obesity Agents; Hypoglycemic Agents; Treatment Outcome; Adult |
| 20 | pmid:41820018 | 2026 | Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes Expert opinion on therapeutic patents · Review | other | Mazdutide | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Peptides; Receptors, Glucagon; Anti-Obesity Agents; Hypoglycemic Agents |
| 21 | pmid:41834765 | 2026 | Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression Diabetes, obesity & metabolism · Meta-Analysis, Comparative Study | other | Cagrilintide | Humans; Obesity; Weight Loss; Blood Glucose; Anti-Obesity Agents; Treatment Outcome; Glucagon-Like Peptides; Randomized Controlled Trials as Topic |
| 22 | pmid:41855048 | 2026 | A review of survodutide: a new dual acting agonist Minerva endocrinology · Review | other | Survodutide | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Somatostatin; Receptors, Glucagon; Hypoglycemic Agents; Glucagon-Like Peptide-1 Receptor Agonists |
| 28 | pmid:42138103 | 2026 | Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning Expert opinion on pharmacotherapy · Review | other | Orforglipron | Animals; Humans; Obesity; Weight Loss; Fluorine Compounds; Oxadiazoles; Anti-Obesity Agents; Administration, Oral |
| 29 | pmid:42166683 | 2026 | The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms Annual review of nutrition · Review | other | Maridebart cafraglutide | Animals; Humans; Obesity; Gastric Inhibitory Polypeptide; Receptors, Gastrointestinal Hormone; Anti-Obesity Agents; Drug Therapy, Combination; Glucagon-Like Peptide 1 |
| 30 | pmid:42175595 | 2026 | Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis Endocrinology, diabetes & metabolism · review-article, Review | other | Eloralintide | Humans; Obesity; Weight Loss; Anti-Obesity Agents; Adult; Overweight; Randomized Controlled Trials as Topic; Islet Amyloid Polypeptide |
| 40 | pmid:42410325 | 2026 | Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis Diabetes, obesity & metabolism · Meta-Analysis, Systematic Review | other | Mazdutide | Humans; Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Peptides; Receptors, Glucagon; Hypoglycemic Agents |
| 41 | pmid:42452898 | 2026 | Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials Diabetes, obesity & metabolism · research-article, Review | other | Eloralintide, Petrelintide | Animals; Humans; Obesity; Weight Loss; Anti-Obesity Agents; Clinical Trials as Topic; Islet Amyloid Polypeptide |
| 42 | pmid:42586227 | 2026 | Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs Pharmacological research · Review | other | Eloralintide, Petrelintide | Animals; Humans; Obesity; Weight Loss; Anti-Obesity Agents; Islet Amyloid Polypeptide; Amylin Receptor Agonists |
| 61 | pmid:40922121 | 2025 | Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis Diabetes, obesity & metabolism · Meta-Analysis, Systematic Review | other | Survodutide | Humans; Diabetes Mellitus, Type 2; Weight Loss; Blood Glucose; Hypoglycemic Agents; Treatment Outcome; Adult; Randomized Controlled Trials as Topic |
| 62 | pmid:41028652 | 2025 | Mazdutide: First Approval Drugs · Review | other | Mazdutide | Humans; Diabetes Mellitus, Type 2; Obesity; Peptides; Receptors, Glucagon; Anti-Obesity Agents; Hypoglycemic Agents; Drug Approval |
| 80 | pmid:31767182 | 2019 | Glucagon-like peptide 1 (GLP-1) Molecular metabolism · Research Support, Non-U.S. Gov't, review-article | other | GLP-1 | Humans; Diabetes Mellitus, Type 2; Obesity; Gastric Inhibitory Polypeptide; Insulin; Glucose; Blood Glucose; Receptors, Glucagon |
| 82 | pmid:29617641 | 2018 | Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Cell metabolism · Research Support, Non-U.S. Gov't, Review | rodent | GLP-1 | Animals; Humans; Mice; Rats; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Obesity; Weight Gain |
| 92 | pmid:26071095 | 2015 | Amylin: Pharmacology, Physiology, and Clinical Potential Pharmacological reviews · Research Support, Non-U.S. Gov't, Review | other | Amylin | Animals; Humans; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Weight Loss; Hypoglycemic Agents; Energy Metabolism; Islet Amyloid Polypeptide |
| 97 | pmid:22236411 | 2012 | Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ (Clinical research ed.) · Meta-Analysis, research-article | other | GLP-1 | Venoms; Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Peptides; Receptors, Glucagon; Anti-Obesity Agents |
| 98 | pmid:21199269 | 2011 | The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis Diabetes, obesity & metabolism · Meta-Analysis, Systematic Review | other | Pramlintide | Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Obesity; Body Weight; Treatment Outcome; Incidence; Female |
| 103 | pmid:16815800 | 2006 | Pancreatic signals controlling food intake; insulin, glucagon and amylin Philosophical transactions of the Royal Society of London. Series B, Biological sciences · research-article, Review | other | Amylin | Pancreas; Animals; Body Weight; Amyloid; Glucagon; Insulin; Eating; Islet Amyloid Polypeptide |
Not a registered trial record — 27 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 3 | pmid:41090431 | 2026 | Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Diabetes, obesity & metabolism · methods-article | other | Retatrutide | Humans; Osteoarthritis, Knee; Sleep Apnea, Obstructive; Obesity; Fatty Acids; Peptides; Double-Blind Method; Adult |
| 9 | pmid:41287212 | 2026 | A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice Diabetes, obesity & metabolism · Comparative Study, research-article | rodent | Maridebart cafraglutide | Liver; Adipose Tissue; Animals; Mice, Inbred C57BL; Mice; Insulin Resistance; Obesity; Body Weight |
| 13 | pmid:41559929 | 2026 | Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept Diabetes, obesity & metabolism · research-article, Multicenter Study | human trial | Eloralintide | Humans; Obesity; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Injections, Subcutaneous; Double-Blind Method; Dose-Response Relationship, Drug |
| 14 | pmid:41638399 | 2026 | Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation Molecular metabolism · research-article | rodent | Survodutide | Brain; Area Postrema; Hypothalamus; Neurons; Animals; Mice, Inbred C57BL; Humans; Mice |
| 17 | pmid:41741376 | 2026 | Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models Obesity (Silver Spring, Md.) · research-article | rodent | Retatrutide | Liver; Animals; Mice, Inbred C57BL; Mesocricetus; Mice; Mice, Obese; Fatty Liver; Insulin Resistance |
| 24 | pmid:41994902 | 2026 | Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight Diabetes, obesity & metabolism · research-article, Multicenter Study | human trial | Orforglipron | Humans; Obesity; Fluorine Compounds; Oxadiazoles; Anti-Obesity Agents; Capsules; Tablets; Administration, Oral |
| 31 | pmid:42207966 | 2026 | Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials Endocrinology, diabetes & metabolism · Comparative Study, research-article | other | Cagrilintide | Humans; Obesity; Weight Loss; Gastric Inhibitory Polypeptide; Anti-Obesity Agents; Treatment Outcome; Overweight; Glucagon-Like Peptide 1 |
| 33 | pmid:42225305 | 2026 | Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison Diabetes, obesity & metabolism · Comparative Study, research-article | other | Orforglipron | Humans; Obesity; Weight Loss; Fluorine Compounds; Oxadiazoles; Anti-Obesity Agents; Body Mass Index; Treatment Outcome |
| 37 | pmid:42260119 | 2026 | A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance Nature metabolism · research-article | rodent | Cagrilintide | Neurons; Vagus Nerve; Animals; Humans; Mice; Rats; Prolactin-Releasing Hormone; Species Specificity |
| 49 | pmid:39868848 | 2025 | Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP Advanced science (Weinheim, Baden-Wurttemberg, Germany) · research-article | rodent | Retatrutide | Cell Line, Tumor; Animals; Humans; Mice; Obesity; Fatty Acids; Peptides; Adaptor Proteins, Signal Transducing |
| 56 | pmid:40608546 | 2025 | Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment Journal of medicinal chemistry · Journal Article | rodent | Petrelintide | Animals; Humans; Mice; Rats; Obesity; Receptors, Calcitonin; Anti-Obesity Agents; Structure-Activity Relationship |
| 57 | pmid:40609154 | 2025 | Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 EBioMedicine · research-article | rodent | Cagrilintide | Brain; Animals; Mice, Knockout; Mice; Obesity; Body Weight; Calcitonin; Receptors, Calcitonin |
| 59 | pmid:40619099 | 2025 | Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide Molecular metabolism · research-article | rodent | Survodutide | Animals; Mice, Inbred C57BL; Humans; Mice; Obesity; Peptide YY; Receptors, Neuropeptide Y; Anti-Obesity Agents |
| 68 | pmid:38599221 | 2024 | Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials Lancet (London, England) · Research Support, Non-U.S. Gov't, research-article | human trial | Semaglutide | Humans; Obesity; Stroke Volume; Treatment Outcome; Double-Blind Method; Aged; Middle Aged; Female |
| 69 | pmid:38740993 | 2024 | Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Nature medicine · Research Support, Non-U.S. Gov't, research-article | human trial | Semaglutide | Humans; Cardiovascular Diseases; Obesity; Weight Loss; Body Mass Index; Treatment Outcome; Double-Blind Method; Adult |
| 71 | pmid:38976257 | 2024 | Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity JAMA internal medicine · Comparative Study, Research Support, Non-U.S. Gov't | other | Semaglutide, Tirzepatide | Humans; Obesity; Weight Loss; Anti-Obesity Agents; Retrospective Studies; Cohort Studies; Adult; Aged |
| 72 | pmid:39222642 | 2024 | Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials Lancet (London, England) · Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't | human trial | Semaglutide | Humans; Diabetes Mellitus, Type 2; Obesity; Stroke Volume; Treatment Outcome; Hospitalization; Aged; Middle Aged |
| 78 | pmid:30341767 | 2019 | Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease Hepatology (Baltimore, Md.) · Comparative Study, Research Support, Non-U.S. Gov't | human trial | Liraglutide | Humans; Diabetes Mellitus, Type 2; Body Weight; Metformin; Blood Glucose; Hypoglycemic Agents; Prognosis; Treatment Outcome |
| 85 | pmid:28237263 | 2017 | 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial Lancet (London, England) · Comparative Study, Research Support, Non-U.S. Gov't | human trial | Liraglutide | Humans; Diabetes Mellitus, Type 2; Prediabetic State; Obesity; Body Weight; Weight Loss; Blood Glucose; Placebos |
| 86 | pmid:28449402 | 2017 | Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial Diabetes, obesity & metabolism · Comparative Study, Research Support, Non-U.S. Gov't | human trial | Lixisenatide | Kidney; Humans; Diabetic Nephropathies; Diabetes Mellitus, Type 2; Insulin; Peptides; Hypoglycemic Agents; Glomerular Filtration Rate |
| 93 | pmid:26308095 | 2015 | Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide Journal of medicinal chemistry · Journal Article | rodent | GLP-1 | Cell Line; Animals; Swine; Swine, Miniature; Humans; Mice, Obese; Rats, Sprague-Dawley; Crystallography, X-Ray |
| 94 | pmid:24467746 | 2014 | GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody Endocrinology · Journal Article | rodent | GLP-1 | Duodenum; Cell Line; Venoms; Animals; Mice, Inbred C57BL; Mice, Knockout; Haplorhini; Humans |
| 95 | pmid:25202980 | 2014 | The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss The Journal of clinical investigation · Research Support, Non-U.S. Gov't, research-article | rodent | GLP-1 | Hypothalamus; Paraventricular Hypothalamic Nucleus; Neurons; Vagus Nerve; Animals; Mice, Transgenic; Mice; Rats |
| 96 | pmid:23728174 | 2013 | Exenatide and the treatment of patients with Parkinson's disease The Journal of clinical investigation · Research Support, Non-U.S. Gov't, research-article | human trial | Exenatide | Venoms; Humans; Parkinson Disease; Disease Progression; Weight Loss; Constipation; Peptides; Antiparkinson Agents |
| 99 | pmid:20094043 | 2010 | Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial Obesity (Silver Spring, Md.) · Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Pramlintide | Humans; Obesity; Weight Loss; Phentermine; Cyclobutanes; Appetite Depressants; Hypoglycemic Agents; Drug Therapy, Combination |
| 100 | pmid:19521351 | 2009 | Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy Obesity (Silver Spring, Md.) · research-article, Multicenter Study | human trial | Pramlintide | Humans; Obesity; Weight Loss; Amyloid; Leptin; Receptors, Peptide; Anti-Obesity Agents; Drug Combinations |
| 101 | pmid:18458326 | 2008 | Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies Proceedings of the National Academy of Sciences of the United States of America · research-article | rodent | Amylin | Hypothalamus; Adipose Tissue; Animals; Rats; Obesity; Disease Models, Animal; Body Weight; Amyloid |
What this page does not say
- It does not say what any record found. Subject headings describe what a record is about, not what it concluded.
- It does not rank the compounds. The column order is fixed by record class and the row order is alphabetical, neither of which carries a judgement.
- It does not represent the literature. The counts are of records this corpus carries; the queries behind them returned 48,938 records in total across the compounds in scope.
- It is not clinical guidance, and it is not reviewed by a clinician. The disclaimer states the limits in full.